Marinus Pharma (MRNS) Reports Q2 Loss of $0.46
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Marinus Pharmaceuticals (MRNS) PT Raised to $3 at Jefferies
August 10, 2016 8:28 AM EDTJefferies analyst Brian Abrahams reiterated a Buy rating and boosted his price target on Marinus Pharmaceuticals (NASDAQ: MRNS) to $3.00 (from $2.50).
Abrahams commented, "Though it has taken some time for ganaxolone to find its optimal indications, based on its GABA mechanism, and promising data from... More
